Abstract:Alteration of the lung microbiome has been observed in several respiratory tract diseases. However, most previous studies were based on 16S ribosomal RNA and shotgun metagenome sequencing; the viability and functional activity of the microbiome, as well as its interaction with host immune systems, have not been well studied. To characterize the active lung microbiome and its associations with host immune response and clinical features, we applied metatranscriptome sequencing to bronchoalveolar lavage fluid (BALF) samples from 25 patients with chronic obstructive pulmonary disease (COPD) and from nine control cases without known pulmonary disease. Community structure analyses revealed three distinct microbial compositions, which were significantly correlated with bacterial biomass, human Th17 immune response, and COPD exacerbation frequency. Specifically, samples with transcriptionally active Streptococcus, Rothia, or Pseudomonas had bacterial loads 16 times higher than samples enriched for Escherichia and Ralstonia. These high-bacterial-load samples also tended to undergo a stronger Th17 immune response. Furthermore, an increased proportion of lymphocytes was found in samples with active Pseudomonas. In addition, COPD patients with active Streptococcus or Rothia infections tended to have lower rates of exacerbations than patients with active Pseudomonas and patients with lower bacterial biomass. Our results support the idea of a stratified structure of the active lung microbiome and a significant host-microbe interaction. We speculate that diverse lung microbiomes exist in the population and that their presence and activities could either influence or reflect different aspects of lung health.IMPORTANCE Recent studies of the microbiome proposed that resident microbes play a beneficial role in maintaining human health. Although lower respiratory tract disease is a leading cause of sickness and mortality, how the lung microbiome interacts with human health remains largely unknown. Here we assessed the association between the lung microbiome and host gene expression, cytokine concentration, and over 20 clinical features. Intriguingly, we found a stratified structure of the active lung microbiome which was significantly associated with bacterial biomass, lymphocyte proportion, human Th17 immune response, and COPD exacerbation frequency. These observations suggest that the microbiome plays a significant role in lung homeostasis. Not only microbial composition but also active functional elements and host immunity characteristics differed among different individuals. Such diversity may partially account for the variation in susceptibility to particular diseases.

Microbiome features and clinical significance in bronchoalveolar lavage fluid of patients with pneumonic-type lung cancer

Transcriptionally Active Lung Microbiome And Its Association With Bacterial Biomass And Host Inflammatory Status

Diagnostic Value of the Microbiome in the Bronchoalveolar Fluid of Patients with Lung masses and its Relationship with their Clinical Features

Characterization of the lung microbiome and exploration of potential bacterial biomarkers for lung cancer

The Microbiome of Lower Respiratory Tract and Tumor Tissue in Lung Cancer Manifested As Radiological Ground-Glass Opacity

A Preliminary Study on Microbiota Characteristics of Bronchoalveolar Lavage Fluid in Patients with Pulmonary Nodules Based on Metagenomic Next-Generation Sequencing

Difference Of Lower Airway Microbiome In Bilateral Protected Specimen Brush Between Lung Cancer Patients With Unilateral Lobar Masses And Control Subjects

Pulmonary microbiota signatures adjacent to adenocarcinoma, squamous cell carcinoma and benign lesion

Prediction of lung cancer using novel biomarkers based on microbiome profiling of bronchoalveolar lavage fluid

The airway microbiota of non‐small cell lung cancer patients and its relationship to tumor stage and EGFR gene mutation

Airway Microbiota in Patients With Synchronous Multiple Primary Lung Cancer: The Bacterial Topography of the Respiratory Tract

Lower respiratory tract microbiome and lung cancer risk prediction in patients with diffuse lung parenchymal lesions

Characterization of Microbiota in Cancerous Lung and the Contralateral Non-Cancerous Lung Within Lung Cancer Patients

The Composition Alteration of Respiratory Microbiota in Lung Cancer

Lung microbiome alterations in NSCLC patients

Higher Microbial Abundance and Diversity in Bronchus-Associated Lymphoid Tissue (BALT) Lymphomas than in Non-Cancerous Lung Tissues

Clinical application of bronchoalveolar lavage fluid metagenomics next-generation sequencing in cancer patients with severe pneumonia

P1.01-44 the Role of Microbiota on the Development of Non-Small-Cell Lung Cancer

Community Dynamics of Fungi During the Progression of Human Non-Small-Cell Lung Cancer

Application of mNGS in the study of pulmonary microbiome in pneumoconiosis complicated with pulmonary infection patients and exploration of potential biomarkers

[Analysis of Salivary Microbiota Characteristics in Patients With Pulmonary Nodules: A Prospective Nonrandomized Concurrent Controlled Trial]